The long term visual results of photocoagulation for diabetic maculopathy were determined in 128 eyes of 95 patients followed over ten years. The mean age of patients was 55.5 years and mean follow up time was 7 years. Ten year data were available on forty patients (62 eyes) and of the remainder the majority had died. Of those eyes initially with good vision (defined as 6/12 or better), 60% maintained this level of acuity at ten years and of those which deteriorated 50% became blind (defined as 6/60 or worse). A significantly greater proportion of eyes with exudative maculopathy (48%) had good final vision compared to eyes with oedematous and ischaemic maculopathy (26%).
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Although photocoagulation has been demon strated to be effective in the treatment of dia betic maculopathy, the condition remains a major cause of visual 10ss.l-4 The visual out come following treatment has previously been determined in several clinical trials with mean durations of patient follow-up ranging from one to five years. 5·8 In order to assess whether or not the benefit of treatment is maintained in the long term we now report the results of a ten year follow-up on patients treated for dia betic maculopathy.
Patients and Methods
Ninety-five consecutive patients referred to the diabetic retinopathy clinic at the Ham mersmith Hospital between 1 January 1974 and 31 December 1976 with diabetic mac ulopathy in at least one eye were entered into the study. Details of these patients are shown in Table I . 
Results
The number of patients and eyes remaining in the study during the ten years is shown in Table II . The mean (±SD) length of patient follow-up was 7.0±3.2 years. Of those 55 patients in whom ten year data was unavail able the majority had died (See Table III ). A total of 36 patients (55 eyes) developed proliferative retinopathy during the course of this study. This represented 37% of the exuda tive eyes and 47% of the non-exudative eyes. In only four of these eyes, which developed vitreous haemorrhages, was the proliferative disease the final cause for the reduced vision. 
62
In order to assess visual outcome, eyes were divided into those with good vision (6/6-6/12), fair vision (6/18--6/36) and poor vision (6/60 or worse).
The initial and final vision of the 62 eyes which achieved a ten year follow-up are shown in Table IV Table V . Although at entry no significant difference was present between the initial visions of the two groups a significantly greater number of eyes in the exudative group had final vision that was good (48%) com pared to the non-exudative group (26%).
Discussion
As reported in previous studies, the majority of patients presenting with diabetic maculo pathy were found to be non-insulin depend ent.IO-ll Our study also confirms that patients with diabetic maculopathy have a reduced life expectancy compared to non-diabetics of a In the British Multicentre Study, photo coagulation was found to be effective in main taining vision in treated eyes compared to control eyes over a five year period. It is notable from our study that most of the deterioration in vision occurred in the first five years after treatment, relatively little occur ring thereafter. This suggests that the visual acuity five years after treatment is a good indi cator of long term visual outcome (see Fig. 1 ). Photocoagulation for diabetic maculopathy is therefore effective in maintaining vision over the long term with 60% of eyes with good vision initially maintaining this level of vision at ten years.
In this study the benefit of treatment was greater for exudative maculopathy than for oedematous maculopathy. Since this study was started, grid photocoagulation has been shown to maintain vision in eyes with diffuse macular oedema.13 The long-term difference in visual outcome between the exudative and non-exudative eyes may therefore be less when this mode of treatment is employed than that reported in this study.
This work was supported by the British Diabetic Association.
